The biopharmaceutical industry commitments to tackle the coronavirus pandemic (Video playlist)
In this video series, IFPMA Director General Thomas Cueni explains the commitments made by the biopharmaceutical industry to step up to the coronavirus public health crisis. There is an unprecedented level of collaboration taking place across the biopharmaceutical industry as it joins with public agencies to accelerate R&D and develop solutions to coronavirus. IFPMA members are committed to work together as one team to achieve one shared goal: containing COVID-19.
The biopharmaceutical industry is united against COVID-19
The biopharmaceutical industry commitments to tackle the coronavirus pandemic
What can we expect from the biopharmaceutical industry?
What is the current state of play in terms of biopharmaceutical R&D to find solutions to COVID-19?
What can we learn from other crisis such as SARS, MERS, Zika and Ebola?
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.Learn more
Media ContactElliot Dunster email@example.com